Randomized Phase II Study of Induction Bevacizumab, Etoposide and Cisplatin Followed by Whole Brain Radiotherapy (WBRT) Versus WBRT Alone in Breast Cancer With Untreated Brain Metastases
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 May 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin; Etoposide
- Indications Brain metastases; Breast cancer
- Focus Therapeutic Use
- Acronyms A-PLUS
- 02 May 2019 Planned End Date changed from 1 Jul 2019 to 1 Dec 2019.
- 02 May 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Sep 2019.
- 02 May 2019 Status changed from recruiting to active, no longer recruiting.